Study shows RAD001 froze kidney cancer for a year
Cuma, 16.05.2008, 01:23am (GMT)
WASHINGTON (Reuters) - Nearly two-thirds of kidney cancer patients taking Novartis AG's RAD001 had progression of their disease delayed by a year, a significantly better result than in those taking placebo, investigators said.
Reuters Health News
|
Yorumlar (0)
Yazdir
Arkadasina Oner
Ust
